Seth Lee
Associate
Dr. Seth Lee is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His practice focuses on patent prosecution and due diligence matters in the fields of biotechnology, therapeutic, genomics, medical devices, artificial intelligence, and additive manufacturing.
Prior to joining the firm, Seth conducted doctoral research on developing biomaterials based on supramolecular chemistry and self-assembly under the supervision of Professor Samuel I. Stupp at Northwestern University. During his postdoctoral research in the laboratory of Professor Helen H. Blau at Stanford University, he studied muscle stem cell biology for muscle regeneration.
Experience
Dr. Seth Lee is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His practice focuses on patent prosecution and due diligence matters in the fields of biotechnology, therapeutic, genomics, medical devices, artificial intelligence, and additive manufacturing.
Prior to joining the firm, Seth conducted doctoral research on developing biomaterials based on supramolecular chemistry and self-assembly under the supervision of Professor Samuel I. Stupp at Northwestern University. During his postdoctoral research in the laboratory of Professor Helen H. Blau at Stanford University, he studied muscle stem cell biology for muscle regeneration.
Education
- J.D., Fordham University School of Law, 2024
- Postdoctoral Scholar, Stanford University, 2017
- Ph.D., Materials Science and Engineering, Northwestern University, 2015Samsung Scholarship Ph.D. Fellow
- B.S., Materials Science and Engineering, Cornell University, 2009
Admissions
- State Bar of California
- U.S. Patent and Trademark Office
Credentials
Education
- J.D., Fordham University School of Law, 2024
- Postdoctoral Scholar, Stanford University, 2017
- Ph.D., Materials Science and Engineering, Northwestern University, 2015Samsung Scholarship Ph.D. Fellow
- B.S., Materials Science and Engineering, Cornell University, 2009
Admissions
- State Bar of California
- U.S. Patent and Trademark Office
Select Publications
- Co-author with T. Fyrner, S. Stupp et al., "Sulfated glycopeptide nanostructures for multipotent protein activation," 12(8) Nature Nanotechnology 821-9, 2017
- Co-author with R. Freeman, N. Stephanopoulos, and S. Stupp et al., "Instructing cells with programmable peptide DNA hybrids," 8(15982) Nature Communications, 2017
- Co-author with E. Pazos, S. Stupp et al., "Nucleation and growth of ordered arrays of silver nanoparticles on peptide nanofibers: hybrid nanostructures with antimicrobial properties," 138(17) Journal of the American Chemical Society 5507-10, 2016
- Co-author with M. Conda-Sheridan, A. Preslar, and S. Stupp, "Esterase-activated release of naproxen from supramolecular nanofibers," 50(89) Chemical Communications, 2014
- Co-author with B. Huang, S. Stupp et al., "Bone regeneration with low dose BMP-2 amplified by biomimetic supramolecular nanofibers within collagen scaffolds," 34(2) Biomaterials 452-9, 2013
- Co-author with Y. Lim, G. Malliaras et al., "Spray-deposited poly(3,4-ethylenedioxythiophene): poly(styrenesulfonate) top electrode for organic solar cells," 93(19) Applied Physics Letters, 2008
Insights
Select Publications
- Co-author with T. Fyrner, S. Stupp et al., "Sulfated glycopeptide nanostructures for multipotent protein activation," 12(8) Nature Nanotechnology 821-9, 2017
- Co-author with R. Freeman, N. Stephanopoulos, and S. Stupp et al., "Instructing cells with programmable peptide DNA hybrids," 8(15982) Nature Communications, 2017
- Co-author with E. Pazos, S. Stupp et al., "Nucleation and growth of ordered arrays of silver nanoparticles on peptide nanofibers: hybrid nanostructures with antimicrobial properties," 138(17) Journal of the American Chemical Society 5507-10, 2016
- Co-author with M. Conda-Sheridan, A. Preslar, and S. Stupp, "Esterase-activated release of naproxen from supramolecular nanofibers," 50(89) Chemical Communications, 2014
- Co-author with B. Huang, S. Stupp et al., "Bone regeneration with low dose BMP-2 amplified by biomimetic supramolecular nanofibers within collagen scaffolds," 34(2) Biomaterials 452-9, 2013
- Co-author with Y. Lim, G. Malliaras et al., "Spray-deposited poly(3,4-ethylenedioxythiophene): poly(styrenesulfonate) top electrode for organic solar cells," 93(19) Applied Physics Letters, 2008
Biological Sciences and Biotechnology
- Cell biology
- Cell therapy
- Immunology
Therapeutics and Drug Discovery
- CRISPR
- Gene editing
Diagnostics and Medical Devices
- Biomedical devices
Chemistry and Material Science
- Protein engineering
Engineering and Technology
- Materials science
- Microfluidics
Genomics and Data Analysis
- Sequencing
Technical Fluency
Biological Sciences and Biotechnology
- Cell biology
- Cell therapy
- Immunology
Therapeutics and Drug Discovery
- CRISPR
- Gene editing
Diagnostics and Medical Devices
- Biomedical devices
Chemistry and Material Science
- Protein engineering
Engineering and Technology
- Materials science
- Microfluidics
Genomics and Data Analysis
- Sequencing
Recent Insights
Client Highlights
Firm Advises Eight Sleep on IP Matters Related to $100 Million Financing
On August 19, 2025, Eight Sleep, the world’s first sleep-fitness company, announced that it has raised $100 million in new funding to accelerate the company’s vision of transforming the bed into an AI-powered sleep-optimization and preventive health device. The round included participation from HSG, Valor Equity Partners, Atreides, Founders Fund, Y Combinator, and notable sports figures, including Charles Leclerc (Ferrari F1 Driver) and Zak Brown (CEO of McLaren F1). Wilson Sonsini Goodrich & Rosati advised Eight Sleep on IP diligence matters related to the transaction.
Eight Sleep will use the funding to supercharge its AI roadmap, starting with the development of the world’s first Sleep Agent. This marks a breakthrough in applying large language models to human physiology, going beyond conversation to deliver real-time, real-world optimization. The funding will also support Eight Sleep’s entry into the medical space, as the company is developing AI-powered solutions for medical sleep challenges, starting with menopausal sleep and sleep apnea. Eight Sleep is also targeting FDA approval for certain applications.
The Wilson Sonsini team advising Eight Sleep on IP matters related to the transaction includes Bill Barrett, Darby Chan, Seth Lee, and Nick Upright.
For more information, please see Eight Sleep’s news release.
Eight Sleep will use the funding to supercharge its AI roadmap, starting with the development of the world’s first Sleep Agent. This marks a breakthrough in applying large language models to human physiology, going beyond conversation to deliver real-time, real-world optimization. The funding will also support Eight Sleep’s entry into the medical space, as the company is developing AI-powered solutions for medical sleep challenges, starting with menopausal sleep and sleep apnea. Eight Sleep is also targeting FDA approval for certain applications.
The Wilson Sonsini team advising Eight Sleep on IP matters related to the transaction includes Bill Barrett, Darby Chan, Seth Lee, and Nick Upright.
For more information, please see Eight Sleep’s news release.
Learn More
Client Highlights
Wilson Sonsini Represents WuXi AppTec in Acquisition of OXGENE
On March 2, 2021, WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries, announced that it has completed its acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. The acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide. Wilson Sonsini Goodrich & Rosati represented WuXi AppTec in the transaction, in collaboration with Taylor Wessing, which served as UK counsel.
OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit. WuXi ATU's integrated platforms transform the development, testing, manufacturing, and commercialization of cell and gene therapy products and accelerate their time to market. OXGENE, which will retain its name, will be WuXi ATU's first facility in Europe and will further enhance these industry-leading capabilities.
The Wilson Sonsini team that represented WuXi AppTec in the transaction included the following:
Corporate
Barry Taylor
Kathy H. Ku
Nikkisha Smith
Rui Ke
London Corporate
Stacy Kim
Amanda Pollard
Jose Campos
OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit. WuXi ATU's integrated platforms transform the development, testing, manufacturing, and commercialization of cell and gene therapy products and accelerate their time to market. OXGENE, which will retain its name, will be WuXi ATU's first facility in Europe and will further enhance these industry-leading capabilities.
The Wilson Sonsini team that represented WuXi AppTec in the transaction included the following:
Corporate
Barry Taylor
Kathy H. Ku
Nikkisha Smith
Rui Ke
London Corporate
Stacy Kim
Amanda Pollard
Jose Campos
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.